Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Theranostics Market Analysis

ID: MRFR/HC/6585-HCR
90 Pages
Kinjoll Dey
December 2024

Theranostics Market Research Report By Application (Oncology, Neurology, Cardiology, Infectious Diseases), By Technology (Genomics, Proteomics, Metabolomics, Biomarkers), By End User (Hospitals, Diagnostic Laboratories, Research Institutes), By Product Type (Instruments, Reagents, Software) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Theranostics Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Market Analysis

In-depth Analysis of Theranostics Market Industry Landscape

Theranostics combines medications and diagnostics into a single, tailored offering for a cutting-edge, holistic healthcare strategy. The market is affected by targeted pharmaceuticals, tailored healthcare, and molecular medicine. Diagnostics and treatment are smoothly integrated with theranostics. Market dynamics are affected by tailored medicine, which utilizes patient traits and diagnostic data to improve treatments. Advanced molecular imaging technologies are essential to theranostics. Imaging innovations like SPECT and PET, which enable precise diagnosis for personalized therapeutic approaches, affect market dynamics. Customized cancer medicines based on tumor characteristics are Theranostics' specialty in oncology. Market dynamics are affected by the demand for specialized medicines that can properly identify cancer and cure it while lowering side effects and improving patient outcomes. Development of radiotheranostics, which mixes diagnostic and therapeutic radionuclides, drives the market. Nuclear medicine approaches like peptide receptor radionuclide treatment and immunotherapy enable new cancer treatment, shaping market dynamics. Companion diagnostics, which detect patients who may respond to specific drugs, affect market dynamics. Theranostics helps doctors create companion diagnostics to tailor treatment to individual patients. Nanomedicine is crucial to theranostics' tailored drug delivery and imaging. Market dynamics are affected by nanocarriers that deliver therapeutic payloads to specified cells or tissues and enable diagnostic imaging to assess treatment efficacy. Growing rates of chronic diseases including cancer, heart disease, and neurological issues affect market dynamics. Theranostics may help manage illnesses, driving the demand for tailored medicines. Alliances between research institutes, diagnostic enterprises, and pharmaceutical companies affect market dynamics. Research and development collaborations advance theranostics applications and commercial innovation. Market dynamics are affected by tight theranostic product regulations. Manufacturers must navigate complex regulatory processes to ensure the safety and efficacy of integrated diagnostics and therapeutics, which influences product acceptability and market access. Patient acceptance and awareness of theranostics affect market dynamics. As patients learn about focused therapies and tailored medicine, their susceptibility to theranostic approaches affects treatment decisions and demand. Insurance coverage and healthcare spending affect market dynamics. Market trends and adoption rates depend on theranostics' financial viability and illness management efficacy.

Author
Author Profile
Kinjoll Dey
Senior Research Analyst

He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

Get In Touch

Leave a Comment

FAQs

What is the current valuation of the Theranostics Market as of 2024?

<p>The Theranostics Market was valued at 9.18 USD Billion in 2024.</p>

What is the projected market size for the Theranostics Market in 2035?

<p>The market is projected to reach 31.21 USD Billion by 2035.</p>

What is the expected CAGR for the Theranostics Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the Theranostics Market during 2025 - 2035 is 11.77%.</p>

Which application segment is anticipated to dominate the Theranostics Market?

<p>The Oncology application segment is expected to grow from 3.0 USD Billion to 10.5 USD Billion.</p>

How does the Neurology segment perform in the Theranostics Market?

<p>The Neurology segment is projected to increase from 1.5 USD Billion to 5.5 USD Billion.</p>

What are the key technologies driving the Theranostics Market?

<p>Key technologies include Genomics, expected to grow from 2.5 USD Billion to 8.0 USD Billion.</p>

Which end-use segment is likely to see the highest growth in the Theranostics Market?

<p>The Hospitals end-use segment is anticipated to expand from 2.75 USD Billion to 9.5 USD Billion.</p>

Who are the leading players in the Theranostics Market?

<p>Key players include Thermo Fisher Scientific, Roche Diagnostics, and Siemens Healthineers.</p>

What is the projected growth for the Biomarkers technology segment?

<p>The Biomarkers segment is expected to grow from 2.0 USD Billion to 7.0 USD Billion.</p>

How does the market for Autoimmune Diseases compare to other segments?

<p>The Autoimmune Diseases segment is projected to increase from 2.48 USD Billion to 7.71 USD Billion.</p>

Market Summary

As per MRFR analysis, the Theranostics Market Size was estimated at 9.18 USD Billion in 2024. The Theranostics industry is projected to grow from 10.26 USD Billion in 2025 to 31.21 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 11.77% during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Theranostics Market is poised for substantial growth driven by personalized medicine and technological advancements.

  • The adoption of personalized medicine continues to reshape treatment paradigms, particularly in oncology, which remains the largest segment. Collaborative development efforts are increasingly prevalent, especially in North America, the largest market for theranostics. Regulatory support for innovation is fostering a conducive environment for advancements in molecular imaging, the largest segment. Rising prevalence of chronic diseases and advancements in biomarker discovery are key drivers propelling market expansion, particularly in the Asia-Pacific region.

Market Size & Forecast

2024 Market Size 9.18 (USD Billion)
2035 Market Size 31.21 (USD Billion)
CAGR (2025 - 2035) 11.77%
Largest Regional Market Share in 2024 North America

Major Players

<a href="thermofisher.com/es/en/home/life-science/stem-cell-research/stem-cell-differentiation/culture-systems-reagents-cardiomyocyte-differentiation.html">Thermo Fisher Scientific</a> (US), Roche Diagnostics (CH), <a href="https://www.siemens-healthineers.com/molecular-imaging/theranostics-journey">Siemens Healthineers</a> (DE), Abbott Laboratories (US), Bristol-Myers Squibb (US), Merck KGaA (DE), Illumina (US), Genomic Health (US), AstraZeneca (GB), Novartis (CH)

Market Trends

The Theranostics Market is currently experiencing a transformative phase, characterized by the integration of therapeutic and diagnostic approaches. This convergence allows for personalized medicine, where treatments are tailored to individual patient profiles based on specific biomarkers. As healthcare systems increasingly prioritize precision medicine, the demand for theranostic solutions appears to be on the rise, shaping key theranostics market trends.

This trend is likely driven by advancements in molecular biology and genomics, including developments in pharmacogenomics theranostics market applications and companion diagnostics such as the pharmacogenomics technology theranostics companion diagnostics cdx market. Furthermore, innovations in the radiopharmaceutical theranostics market are enhancing treatment targeting and improving clinical outcomes.

In addition, the Theranostics Market is witnessing a surge in collaborations between pharmaceutical companies and diagnostic firms. Such partnerships aim to streamline the development of companion diagnostics that accompany targeted therapies, thereby ensuring that patients receive the most appropriate treatments. Overall, the theranostics market seems poised for continued growth.

Personalized Medicine Adoption

The Theranostics Market is increasingly leaning towards personalized medicine, where treatments are customized based on individual patient profiles. This trend supports expansion in the radiopharmaceutical theranostics market share, as targeted radionuclide therapies become more prevalent. This trend is fueled by advancements in genomics and molecular biology, enabling healthcare providers to tailor therapies to specific biomarkers, thereby improving treatment effectiveness.

Collaborative Development Efforts

There is a notable rise in collaborations between pharmaceutical companies and diagnostic firms within the Theranostics Market. These partnerships focus on developing companion diagnostics that ensure patients receive the most suitable therapies, thereby enhancing the overall treatment process and strengthening overall theranostics market share.

Regulatory Adaptations

Regulatory bodies are evolving to accommodate the unique needs of the Theranostics Market. This adaptation may lead to streamlined approval processes for theranostic products, facilitating quicker access to innovative therapies and diagnostics for patients.

Theranostics Market Market Drivers

Market Growth Projections

The Global Theranostics Market Industry is poised for substantial growth, with projections indicating a rise from 9.57 USD Billion in 2024 to 31.2 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate of 11.34% from 2025 to 2035, highlighting the increasing adoption of theranostic approaches in clinical practice. Factors contributing to this growth include advancements in technology, rising demand for personalized medicine, and an increasing prevalence of chronic diseases. The market's expansion reflects a broader trend towards integrated healthcare solutions that combine diagnostics and therapeutics, ultimately aiming to improve patient outcomes and optimize treatment efficacy.

Supportive Regulatory Framework

A supportive regulatory framework is fostering growth within the Global Theranostics Market Industry. Regulatory bodies are increasingly recognizing the importance of theranostic approaches, leading to streamlined approval processes for new diagnostic and therapeutic agents. This regulatory support encourages innovation and investment in the development of novel theranostic products. For example, the FDA has established guidelines that facilitate the co-development of diagnostics and therapeutics, which is essential for the success of theranostic strategies. As a result, the market is likely to benefit from an influx of new products and technologies, further driving its expansion in the coming years.

Rising Demand for Personalized Medicine

The Global Theranostics Market Industry is experiencing a notable surge in demand for personalized medicine, which tailors treatment based on individual patient profiles. This shift is largely driven by advancements in genomic and molecular profiling technologies, enabling healthcare providers to identify specific biomarkers associated with diseases. As a result, therapies can be customized, enhancing efficacy and minimizing adverse effects. The market is projected to reach 9.57 USD Billion in 2024, reflecting the growing inclination towards precision medicine. This trend not only improves patient outcomes but also aligns with the broader healthcare paradigm shift towards individualized treatment strategies.

Increasing Incidence of Chronic Diseases

The Global Theranostics Market Industry is significantly impacted by the rising incidence of chronic diseases, including cancer, cardiovascular disorders, and diabetes. As these conditions become more prevalent globally, there is an urgent need for effective diagnostic and therapeutic solutions. Theranostics Market offers a dual approach by providing precise diagnostics alongside targeted therapies, which is particularly beneficial in managing chronic diseases. The market's projected compound annual growth rate of 11.34% from 2025 to 2035 reflects the increasing demand for integrated treatment solutions. This trend indicates a shift towards more comprehensive healthcare strategies that address both diagnosis and treatment in a cohesive manner.

Growing Investment in Research and Development

Investment in research and development is a critical driver of the Global Theranostics Market Industry. Pharmaceutical and biotechnology companies are increasingly allocating resources towards the discovery of new theranostic agents, recognizing the potential for improved patient outcomes and market growth. Collaborative efforts between academia and industry are also on the rise, leading to innovative solutions that bridge the gap between diagnostics and therapeutics. This trend is expected to contribute to the market's growth trajectory, with projections indicating a rise to 31.2 USD Billion by 2035. The emphasis on R&D not only enhances the therapeutic landscape but also positions companies competitively in a rapidly evolving market.

Technological Advancements in Diagnostic Tools

Technological innovations in diagnostic tools are significantly influencing the Global Theranostics Market Industry. The integration of artificial intelligence and machine learning in diagnostic processes enhances the accuracy and speed of disease detection. For instance, advanced imaging techniques and molecular diagnostics are now capable of identifying diseases at earlier stages, which is crucial for effective treatment. The anticipated growth of the market to 31.2 USD Billion by 2035 underscores the impact of these technological advancements. Furthermore, the continuous evolution of diagnostic technologies is likely to facilitate the development of new theranostic agents, thereby expanding treatment options for patients.

Market Segment Insights

By Application: Oncology (Largest) vs. Neurology (Fastest-Growing)

In the Theranostics Market, Oncology stands out as the largest segment, capturing a substantial share due to the increasing prevalence of cancer and advancements in <a href="https://www.marketresearchfuture.com/reports/precision-medicine-market-925">precision medicine</a>. Neurology, while smaller, is emerging with rapid growth as novel therapeutics and diagnostics for neurological disorders gain traction. Infectious Diseases, Autoimmune Diseases, and Cardiology follow, contributing to a diverse landscape of applications that highlight the medical community's focus on personalized treatment pathways. The market's segmentation underscores the critical areas where theranostics can provide significant clinical benefits, ultimately enhancing patient outcomes through tailored therapies.

Oncology: Dominant vs. Neurology: Emerging

Oncology remains the dominant application in the Theranostics Market, driven by significant investments in cancer research and the development of targeted therapies that optimize patient responses. The integration of molecular imaging and biomarker identification enhances personalized treatment strategies, making it a critical focus for healthcare providers. Conversely, Neurology is an emerging segment characterized by innovative approaches to treat complex disorders such as Alzheimer's and Multiple Sclerosis. Advances in neuroimaging and the introduction of biomarker-guided therapy are propelling growth, positioning Neurology as a vital area for future development in theranostics. Innovations in both fields reflect a broader trend toward personalized medicine that addresses unique patient profiles.

By Technology: Molecular Imaging (Largest) vs. Biomarkers (Fastest-Growing)

Molecular Imaging stands as the dominant technology in the Theranostics Market, while Biomarkers are gaining traction due to growth in the pharmacogenomics theranostics market.  This approach has become integral in enhancing patient outcomes by providing real-time imaging capabilities that guide therapeutic decisions. Biomarkers, while smaller in market share, demonstrate rapid growth due to increased investments in personalized medicine, which necessitates the identification and validation of specific biological indicators that can predict treatment responses.

Technology: Molecular Imaging (Dominant) vs. Biomarkers (Emerging)

Molecular imaging is currently the dominant force in the Theranostics Market, offering highly detailed insights into patient conditions and therapeutic effectiveness. Its techniques, such as PET and MRI, are integral in guiding treatment decisions. Conversely, biomarkers represent an emerging segment, critical for their role in predicting disease progression and treatment efficacy. As the shift towards personalized medicine accelerates, biomarkers are witnessing rapid adoption due to their ability to enhance clinical trial outcomes and facilitate targeted therapies, positioning them for significant growth alongside existing technologies.

By End Use: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

In the Theranostics Market, the end use segment is notably diverse, comprising hospitals, diagnostic laboratories, research institutions, pharmaceutical companies, and academic institutions. Hospitals hold the largest market share, driven by the increasing demand for personalized medicine and targeted therapies that enable more effective treatment protocols. Diagnostic laboratories are increasingly important in this landscape, providing crucial testing services and technologies that support theranostic applications, thus securing a significant portion of the market earnings.

Hospitals (Dominant) vs. Diagnostic Laboratories (Emerging)

Hospitals play a pivotal role in the Theranostics Market, serving as both treatment centers and facilitators of personalized healthcare strategies. Their dominant position is underscored by significant investments in advanced diagnostic and treatment technologies, ensuring tailored therapeutic approaches. Conversely, diagnostic laboratories are emerging as essential players in this market, driven by innovations in testing methodologies and an increase in precision medicine initiatives. Their agility in adopting new technologies and efficiently processing patient data enhances their competitiveness, which is vital as healthcare systems demand rapid, reliable diagnostic capabilities that align with theranostic advancements.

Get more detailed insights about Theranostics Market Research Report - Global Forecast till 2035

Regional Insights

North America : Market Leader in Theranostics

North America is poised to maintain its leadership in the Theranostics market, holding a significant market share of 4.5 in 2024. North America is poised to maintain leadership, supported by strong adoption trends and expansion within the north america radiopharmaceutical theranostics market.  Regulatory support from agencies like the FDA further catalyzes innovation and adoption of theranostic solutions, enhancing patient outcomes and treatment efficacy. The competitive landscape in North America is robust, featuring key players such as Thermo Fisher Scientific, Abbott Laboratories, and Genomic Health. The U.S. leads the market, supported by substantial investments in research and development. The presence of major pharmaceutical companies like Bristol-Myers Squibb and Merck KGaA also strengthens the market, fostering collaborations and advancements in theranostic technologies.

Europe : Emerging Market with Growth Potential

Europe is witnessing a growing interest in the Theranostics market, with a market size of 2.5 in 2024. Europe continues to grow steadily, with expansion across the europe theranostics market, including strong contributions from Germany, Switzerland, and the italy theranostics market, as well as increasing adoption within the spain theranostics market and uk theranostics market. Increasing investments in healthcare technology and rising awareness about the benefits of theranostics are key growth drivers. Countries like Germany and Switzerland are at the forefront, supported by favorable policies and funding for innovative healthcare solutions. The competitive landscape in Europe includes major players such as Roche Diagnostics and Siemens Healthineers. Germany is a leading country in the market, with a strong emphasis on research and development. The presence of regulatory bodies ensures compliance and safety, fostering a conducive environment for market growth. As the demand for personalized treatment options rises, Europe is set to become a significant player in The Theranostics.

Asia-Pacific : Rapidly Growing Market Segment

The Asia-Pacific region is emerging as a significant player in the Theranostics market, with a market size of 1.8 in 2024. The asia pacific theranostics market is emerging as a significant growth driver, with rising adoption across the china theranostics market and india theranostics market, supported by improving healthcare infrastructure. Countries like China and India are investing heavily in healthcare infrastructure, which is expected to boost the adoption of theranostic technologies. Regulatory support is also improving, facilitating market entry for innovative solutions. In the competitive landscape, local and international players are vying for market share. Companies like Illumina and AstraZeneca are expanding their presence in the region, capitalizing on the growing demand for advanced diagnostic solutions. The increasing prevalence of chronic diseases further propels the need for personalized treatment options, making Asia-Pacific a key region for future growth in the Theranostics market.

Middle East and Africa : Emerging Market with Challenges

The Middle East and Africa (MEA) region is gradually developing its Theranostics market, currently valued at 0.38 in 2024. Growth opportunities are expanding within the MEA region, including the evolving gcc theranostics market, driven by increased healthcare investments. However, increasing investments in healthcare and rising awareness about personalized medicine are driving demand. Countries like South Africa and the UAE are making strides in improving healthcare access, which may enhance the adoption of theranostic solutions in the future. The competitive landscape in MEA is still in its nascent stages, with few key players establishing a foothold. Local companies are beginning to collaborate with international firms to enhance their capabilities. As healthcare systems evolve and regulatory frameworks improve, the region is expected to see gradual growth in the Theranostics market, presenting opportunities for innovation and investment.

Key Players and Competitive Insights

The Theranostics Market is currently characterized by a dynamic competitive landscape, driven by advancements in personalized medicine and the increasing demand for targeted therapies. Key players such as Thermo Fisher Scientific (US), Roche Diagnostics (CH), and Siemens Healthineers (DE) are at the forefront, leveraging innovation and strategic partnerships to enhance their market positions. For instance, Thermo Fisher Scientific (US) has focused on expanding its portfolio through acquisitions and collaborations, which appears to strengthen its capabilities in precision medicine. Similarly, Roche Diagnostics (CH) emphasizes its commitment to research and development, aiming to integrate cutting-edge technologies into its diagnostic solutions, thereby enhancing its competitive edge. The business tactics employed by these companies include localizing manufacturing and optimizing supply chains to improve efficiency and responsiveness to market demands. The competitive structure of the Theranostics Market is moderately fragmented, with several players vying for market share. However, the collective influence of major companies shapes the market dynamics, as they engage in strategic collaborations and innovations that set industry standards. In November 2025, Roche Diagnostics (CH) announced a partnership with a leading biotechnology firm to develop a novel theranostic platform aimed at improving patient outcomes in oncology. This collaboration is strategically significant as it not only enhances Roche's product offerings but also positions the company to capitalize on the growing trend of personalized cancer therapies. Furthermore, in October 2025, Siemens Healthineers (DE) launched a new imaging solution that integrates AI capabilities to enhance diagnostic accuracy. This move reflects Siemens' commitment to digital transformation and its potential to redefine diagnostic workflows in theranostics. In September 2025, Illumina (US) unveiled a new genomic sequencing technology that promises to accelerate the development of personalized therapies. This innovation is crucial as it aligns with the increasing demand for precision medicine, potentially allowing for more tailored treatment options for patients. Additionally, in August 2025, Bristol-Myers Squibb (US) expanded its collaboration with a prominent research institution to explore novel biomarkers for therapeutic response, indicating a strategic focus on enhancing its drug development pipeline through innovative research. As of December 2025, current competitive trends in the Theranostics Market include a pronounced shift towards digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the landscape, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is likely to evolve, with a greater emphasis on technological advancements and supply chain reliability, rather than solely on price. This shift suggests that companies that prioritize innovation and adaptability will be better positioned to thrive in the evolving market.

Key Companies in the Theranostics Market include

Industry Developments

Recent developments in the Global Theranostics Market have indicated significant progress, particularly with companies such as Bristol-Myers Squibb and Merck & Co. engaging in advanced therapeutic approaches. Siemens Healthineers has recently showcased innovations in diagnostic imaging that enhance theranostic capabilities, aligning with the growing demand for personalized medicine. Qiagen and Illumina continue to evolve their genomic testing technologies, paving the way for tailored treatment solutions. Moreover, Genomic Health's enhancing collaboration with Hoffmann-La Roche aims to bolster cancer diagnosis and treatment strategies.

The market has witnessed notable growth, with Abbott Laboratories and Myriad Genetics expanding their product portfolios, thereby driving the valuation of the sector upward. AstraZeneca and Pfizer are actively involved in mergers and acquisitions to strengthen their therapeutic offerings, with recent acquisitions adding to a robust pipeline of novel therapies. Roche Holding's efforts to integrate precision medicine into clinical settings are contributing to a more comprehensive market landscape. The overall momentum in the theranostics sector reflects a shift towards targeted therapeutics and improved patient outcomes, underscoring a dynamic phase of growth and innovation.

Future Outlook

Theranostics Market Future Outlook

The Theranostics Market is projected to grow at an 11.77% CAGR from 2025 to 2035, driven by advancements in personalized medicine, increased R&amp;D investments, and rising demand for targeted therapies.

New opportunities lie in:

  • <p>Development of integrated diagnostic-therapeutic platforms Expansion of companion diagnostics for oncology Partnerships with biotech firms for innovative biomarker discovery</p>

By 2035, the Theranostics Market is expected to achieve substantial growth, solidifying its role in precision medicine.

Market Segmentation

Theranostics Market End Use Outlook

  • Hospitals
  • Diagnostic Laboratories
  • Research Institutions
  • Pharmaceutical Companies
  • Academic Institutions

Theranostics Market Technology Outlook

  • Molecular Imaging
  • Biomarkers
  • Genomics
  • Proteomics
  • Metabolomics

Theranostics Market Application Outlook

  • Oncology
  • Neurology
  • Cardiology
  • Infectious Diseases
  • Autoimmune Diseases

Report Scope

MARKET SIZE 2024 9.18(USD Billion)
MARKET SIZE 2025 10.26(USD Billion)
MARKET SIZE 2035 31.21(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 11.77% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled Thermo Fisher Scientific (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Abbott Laboratories (US), Bristol-Myers Squibb (US), Merck KGaA (DE), Illumina (US), Genomic Health (US), AstraZeneca (GB), Novartis (CH)
Segments Covered Application, Technology, End Use
Key Market Opportunities Integration of artificial intelligence in diagnostics enhances personalized treatment strategies in the Theranostics Market.
Key Market Dynamics Rising demand for personalized medicine drives innovation and competition in the Theranostics Market.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the current valuation of the Theranostics Market as of 2024?

<p>The Theranostics Market was valued at 9.18 USD Billion in 2024.</p>

What is the projected market size for the Theranostics Market in 2035?

<p>The market is projected to reach 31.21 USD Billion by 2035.</p>

What is the expected CAGR for the Theranostics Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the Theranostics Market during 2025 - 2035 is 11.77%.</p>

Which application segment is anticipated to dominate the Theranostics Market?

<p>The Oncology application segment is expected to grow from 3.0 USD Billion to 10.5 USD Billion.</p>

How does the Neurology segment perform in the Theranostics Market?

<p>The Neurology segment is projected to increase from 1.5 USD Billion to 5.5 USD Billion.</p>

What are the key technologies driving the Theranostics Market?

<p>Key technologies include Genomics, expected to grow from 2.5 USD Billion to 8.0 USD Billion.</p>

Which end-use segment is likely to see the highest growth in the Theranostics Market?

<p>The Hospitals end-use segment is anticipated to expand from 2.75 USD Billion to 9.5 USD Billion.</p>

Who are the leading players in the Theranostics Market?

<p>Key players include Thermo Fisher Scientific, Roche Diagnostics, and Siemens Healthineers.</p>

What is the projected growth for the Biomarkers technology segment?

<p>The Biomarkers segment is expected to grow from 2.0 USD Billion to 7.0 USD Billion.</p>

How does the market for Autoimmune Diseases compare to other segments?

<p>The Autoimmune Diseases segment is projected to increase from 2.48 USD Billion to 7.71 USD Billion.</p>

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. | 1.1 EXECUTIVE SUMMARY
    2. | | 1.1.1 Market Overview
    3. | | 1.1.2 Key Findings
    4. | | 1.1.3 Market Segmentation
    5. | | 1.1.4 Competitive Landscape
    6. | | 1.1.5 Challenges and Opportunities
    7. | | 1.1.6 Future Outlook
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. | 2.1 MARKET INTRODUCTION
    2. | | 2.1.1 Definition
    3. | | 2.1.2 Scope of the study
    4. | | | 2.1.2.1 Research Objective
    5. | | | 2.1.2.2 Assumption
    6. | | | 2.1.2.3 Limitations
    7. | 2.2 RESEARCH METHODOLOGY
    8. | | 2.2.1 Overview
    9. | | 2.2.2 Data Mining
    10. | | 2.2.3 Secondary Research
    11. | | 2.2.4 Primary Research
    12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
    13. | | | 2.2.4.2 Breakdown of Primary Respondents
    14. | | 2.2.5 Forecasting Model
    15. | | 2.2.6 Market Size Estimation
    16. | | | 2.2.6.1 Bottom-Up Approach
    17. | | | 2.2.6.2 Top-Down Approach
    18. | | 2.2.7 Data Triangulation
    19. | | 2.2.8 Validation
  3. SECTION III: QUALITATIVE ANALYSIS
    1. | 3.1 MARKET DYNAMICS
    2. | | 3.1.1 Overview
    3. | | 3.1.2 Drivers
    4. | | 3.1.3 Restraints
    5. | | 3.1.4 Opportunities
    6. | 3.2 MARKET FACTOR ANALYSIS
    7. | | 3.2.1 Value chain Analysis
    8. | | 3.2.2 Porter's Five Forces Analysis
    9. | | | 3.2.2.1 Bargaining Power of Suppliers
    10. | | | 3.2.2.2 Bargaining Power of Buyers
    11. | | | 3.2.2.3 Threat of New Entrants
    12. | | | 3.2.2.4 Threat of Substitutes
    13. | | | 3.2.2.5 Intensity of Rivalry
    14. | | 3.2.3 COVID-19 Impact Analysis
    15. | | | 3.2.3.1 Market Impact Analysis
    16. | | | 3.2.3.2 Regional Impact
    17. | | | 3.2.3.3 Opportunity and Threat Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. | 4.1 Healthcare, BY Application (USD Billion)
    2. | | 4.1.1 Oncology
    3. | | 4.1.2 Neurology
    4. | | 4.1.3 Cardiology
    5. | | 4.1.4 Infectious Diseases
    6. | | 4.1.5 Autoimmune Diseases
    7. | 4.2 Healthcare, BY Technology (USD Billion)
    8. | | 4.2.1 Molecular Imaging
    9. | | 4.2.2 Biomarkers
    10. | | 4.2.3 Genomics
    11. | | 4.2.4 Proteomics
    12. | | 4.2.5 Metabolomics
    13. | 4.3 Healthcare, BY End Use (USD Billion)
    14. | | 4.3.1 Hospitals
    15. | | 4.3.2 Diagnostic Laboratories
    16. | | 4.3.3 Research Institutions
    17. | | 4.3.4 Pharmaceutical Companies
    18. | | 4.3.5 Academic Institutions
    19. | 4.4 Healthcare, BY Region (USD Billion)
    20. | | 4.4.1 North America
    21. | | | 4.4.1.1 US
    22. | | | 4.4.1.2 Canada
    23. | | 4.4.2 Europe
    24. | | | 4.4.2.1 Germany
    25. | | | 4.4.2.2 UK
    26. | | | 4.4.2.3 France
    27. | | | 4.4.2.4 Russia
    28. | | | 4.4.2.5 Italy
    29. | | | 4.4.2.6 Spain
    30. | | | 4.4.2.7 Rest of Europe
    31. | | 4.4.3 APAC
    32. | | | 4.4.3.1 China
    33. | | | 4.4.3.2 India
    34. | | | 4.4.3.3 Japan
    35. | | | 4.4.3.4 South Korea
    36. | | | 4.4.3.5 Malaysia
    37. | | | 4.4.3.6 Thailand
    38. | | | 4.4.3.7 Indonesia
    39. | | | 4.4.3.8 Rest of APAC
    40. | | 4.4.4 South America
    41. | | | 4.4.4.1 Brazil
    42. | | | 4.4.4.2 Mexico
    43. | | | 4.4.4.3 Argentina
    44. | | | 4.4.4.4 Rest of South America
    45. | | 4.4.5 MEA
    46. | | | 4.4.5.1 GCC Countries
    47. | | | 4.4.5.2 South Africa
    48. | | | 4.4.5.3 Rest of MEA
  5. SECTION V: COMPETITIVE ANALYSIS
    1. | 5.1 Competitive Landscape
    2. | | 5.1.1 Overview
    3. | | 5.1.2 Competitive Analysis
    4. | | 5.1.3 Market share Analysis
    5. | | 5.1.4 Major Growth Strategy in the Healthcare
    6. | | 5.1.5 Competitive Benchmarking
    7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
    8. | | 5.1.7 Key developments and growth strategies
    9. | | | 5.1.7.1 New Product Launch/Service Deployment
    10. | | | 5.1.7.2 Merger & Acquisitions
    11. | | | 5.1.7.3 Joint Ventures
    12. | | 5.1.8 Major Players Financial Matrix
    13. | | | 5.1.8.1 Sales and Operating Income
    14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
    15. | 5.2 Company Profiles
    16. | | 5.2.1 Thermo Fisher Scientific (US)
    17. | | | 5.2.1.1 Financial Overview
    18. | | | 5.2.1.2 Products Offered
    19. | | | 5.2.1.3 Key Developments
    20. | | | 5.2.1.4 SWOT Analysis
    21. | | | 5.2.1.5 Key Strategies
    22. | | 5.2.2 Roche Diagnostics (CH)
    23. | | | 5.2.2.1 Financial Overview
    24. | | | 5.2.2.2 Products Offered
    25. | | | 5.2.2.3 Key Developments
    26. | | | 5.2.2.4 SWOT Analysis
    27. | | | 5.2.2.5 Key Strategies
    28. | | 5.2.3 Siemens Healthineers (DE)
    29. | | | 5.2.3.1 Financial Overview
    30. | | | 5.2.3.2 Products Offered
    31. | | | 5.2.3.3 Key Developments
    32. | | | 5.2.3.4 SWOT Analysis
    33. | | | 5.2.3.5 Key Strategies
    34. | | 5.2.4 Abbott Laboratories (US)
    35. | | | 5.2.4.1 Financial Overview
    36. | | | 5.2.4.2 Products Offered
    37. | | | 5.2.4.3 Key Developments
    38. | | | 5.2.4.4 SWOT Analysis
    39. | | | 5.2.4.5 Key Strategies
    40. | | 5.2.5 Bristol-Myers Squibb (US)
    41. | | | 5.2.5.1 Financial Overview
    42. | | | 5.2.5.2 Products Offered
    43. | | | 5.2.5.3 Key Developments
    44. | | | 5.2.5.4 SWOT Analysis
    45. | | | 5.2.5.5 Key Strategies
    46. | | 5.2.6 Merck KGaA (DE)
    47. | | | 5.2.6.1 Financial Overview
    48. | | | 5.2.6.2 Products Offered
    49. | | | 5.2.6.3 Key Developments
    50. | | | 5.2.6.4 SWOT Analysis
    51. | | | 5.2.6.5 Key Strategies
    52. | | 5.2.7 Genomic Health (US)
    53. | | | 5.2.7.1 Financial Overview
    54. | | | 5.2.7.2 Products Offered
    55. | | | 5.2.7.3 Key Developments
    56. | | | 5.2.7.4 SWOT Analysis
    57. | | | 5.2.7.5 Key Strategies
    58. | | 5.2.8 Illumina (US)
    59. | | | 5.2.8.1 Financial Overview
    60. | | | 5.2.8.2 Products Offered
    61. | | | 5.2.8.3 Key Developments
    62. | | | 5.2.8.4 SWOT Analysis
    63. | | | 5.2.8.5 Key Strategies
    64. | | 5.2.9 AstraZeneca (GB)
    65. | | | 5.2.9.1 Financial Overview
    66. | | | 5.2.9.2 Products Offered
    67. | | | 5.2.9.3 Key Developments
    68. | | | 5.2.9.4 SWOT Analysis
    69. | | | 5.2.9.5 Key Strategies
    70. | 5.3 Appendix
    71. | | 5.3.1 References
    72. | | 5.3.2 Related Reports
  6. LIST OF FIGURES
    1. | 6.1 MARKET SYNOPSIS
    2. | 6.2 NORTH AMERICA MARKET ANALYSIS
    3. | 6.3 US MARKET ANALYSIS BY APPLICATION
    4. | 6.4 US MARKET ANALYSIS BY TECHNOLOGY
    5. | 6.5 US MARKET ANALYSIS BY END USE
    6. | 6.6 CANADA MARKET ANALYSIS BY APPLICATION
    7. | 6.7 CANADA MARKET ANALYSIS BY TECHNOLOGY
    8. | 6.8 CANADA MARKET ANALYSIS BY END USE
    9. | 6.9 EUROPE MARKET ANALYSIS
    10. | 6.10 GERMANY MARKET ANALYSIS BY APPLICATION
    11. | 6.11 GERMANY MARKET ANALYSIS BY TECHNOLOGY
    12. | 6.12 GERMANY MARKET ANALYSIS BY END USE
    13. | 6.13 UK MARKET ANALYSIS BY APPLICATION
    14. | 6.14 UK MARKET ANALYSIS BY TECHNOLOGY
    15. | 6.15 UK MARKET ANALYSIS BY END USE
    16. | 6.16 FRANCE MARKET ANALYSIS BY APPLICATION
    17. | 6.17 FRANCE MARKET ANALYSIS BY TECHNOLOGY
    18. | 6.18 FRANCE MARKET ANALYSIS BY END USE
    19. | 6.19 RUSSIA MARKET ANALYSIS BY APPLICATION
    20. | 6.20 RUSSIA MARKET ANALYSIS BY TECHNOLOGY
    21. | 6.21 RUSSIA MARKET ANALYSIS BY END USE
    22. | 6.22 ITALY MARKET ANALYSIS BY APPLICATION
    23. | 6.23 ITALY MARKET ANALYSIS BY TECHNOLOGY
    24. | 6.24 ITALY MARKET ANALYSIS BY END USE
    25. | 6.25 SPAIN MARKET ANALYSIS BY APPLICATION
    26. | 6.26 SPAIN MARKET ANALYSIS BY TECHNOLOGY
    27. | 6.27 SPAIN MARKET ANALYSIS BY END USE
    28. | 6.28 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
    29. | 6.29 REST OF EUROPE MARKET ANALYSIS BY TECHNOLOGY
    30. | 6.30 REST OF EUROPE MARKET ANALYSIS BY END USE
    31. | 6.31 APAC MARKET ANALYSIS
    32. | 6.32 CHINA MARKET ANALYSIS BY APPLICATION
    33. | 6.33 CHINA MARKET ANALYSIS BY TECHNOLOGY
    34. | 6.34 CHINA MARKET ANALYSIS BY END USE
    35. | 6.35 INDIA MARKET ANALYSIS BY APPLICATION
    36. | 6.36 INDIA MARKET ANALYSIS BY TECHNOLOGY
    37. | 6.37 INDIA MARKET ANALYSIS BY END USE
    38. | 6.38 JAPAN MARKET ANALYSIS BY APPLICATION
    39. | 6.39 JAPAN MARKET ANALYSIS BY TECHNOLOGY
    40. | 6.40 JAPAN MARKET ANALYSIS BY END USE
    41. | 6.41 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
    42. | 6.42 SOUTH KOREA MARKET ANALYSIS BY TECHNOLOGY
    43. | 6.43 SOUTH KOREA MARKET ANALYSIS BY END USE
    44. | 6.44 MALAYSIA MARKET ANALYSIS BY APPLICATION
    45. | 6.45 MALAYSIA MARKET ANALYSIS BY TECHNOLOGY
    46. | 6.46 MALAYSIA MARKET ANALYSIS BY END USE
    47. | 6.47 THAILAND MARKET ANALYSIS BY APPLICATION
    48. | 6.48 THAILAND MARKET ANALYSIS BY TECHNOLOGY
    49. | 6.49 THAILAND MARKET ANALYSIS BY END USE
    50. | 6.50 INDONESIA MARKET ANALYSIS BY APPLICATION
    51. | 6.51 INDONESIA MARKET ANALYSIS BY TECHNOLOGY
    52. | 6.52 INDONESIA MARKET ANALYSIS BY END USE
    53. | 6.53 REST OF APAC MARKET ANALYSIS BY APPLICATION
    54. | 6.54 REST OF APAC MARKET ANALYSIS BY TECHNOLOGY
    55. | 6.55 REST OF APAC MARKET ANALYSIS BY END USE
    56. | 6.56 SOUTH AMERICA MARKET ANALYSIS
    57. | 6.57 BRAZIL MARKET ANALYSIS BY APPLICATION
    58. | 6.58 BRAZIL MARKET ANALYSIS BY TECHNOLOGY
    59. | 6.59 BRAZIL MARKET ANALYSIS BY END USE
    60. | 6.60 MEXICO MARKET ANALYSIS BY APPLICATION
    61. | 6.61 MEXICO MARKET ANALYSIS BY TECHNOLOGY
    62. | 6.62 MEXICO MARKET ANALYSIS BY END USE
    63. | 6.63 ARGENTINA MARKET ANALYSIS BY APPLICATION
    64. | 6.64 ARGENTINA MARKET ANALYSIS BY TECHNOLOGY
    65. | 6.65 ARGENTINA MARKET ANALYSIS BY END USE
    66. | 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
    67. | 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY TECHNOLOGY
    68. | 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USE
    69. | 6.69 MEA MARKET ANALYSIS
    70. | 6.70 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
    71. | 6.71 GCC COUNTRIES MARKET ANALYSIS BY TECHNOLOGY
    72. | 6.72 GCC COUNTRIES MARKET ANALYSIS BY END USE
    73. | 6.73 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
    74. | 6.74 SOUTH AFRICA MARKET ANALYSIS BY TECHNOLOGY
    75. | 6.75 SOUTH AFRICA MARKET ANALYSIS BY END USE
    76. | 6.76 REST OF MEA MARKET ANALYSIS BY APPLICATION
    77. | 6.77 REST OF MEA MARKET ANALYSIS BY TECHNOLOGY
    78. | 6.78 REST OF MEA MARKET ANALYSIS BY END USE
    79. | 6.79 KEY BUYING CRITERIA OF HEALTHCARE
    80. | 6.80 RESEARCH PROCESS OF MRFR
    81. | 6.81 DRO ANALYSIS OF HEALTHCARE
    82. | 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    83. | 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    84. | 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE
    85. | 6.85 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    86. | 6.86 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
    87. | 6.87 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
    88. | 6.88 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Billion)
    89. | 6.89 HEALTHCARE, BY END USE, 2024 (% SHARE)
    90. | 6.90 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion)
    91. | 6.91 BENCHMARKING OF MAJOR COMPETITORS
  7. LIST OF TABLES
    1. | 7.1 LIST OF ASSUMPTIONS
    2. | | 7.1.1
    3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
    4. | | 7.2.1 BY APPLICATION, 2025-2035 (USD Billion)
    5. | | 7.2.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
    6. | | 7.2.3 BY END USE, 2025-2035 (USD Billion)
    7. | 7.3 US MARKET SIZE ESTIMATES; FORECAST
    8. | | 7.3.1 BY APPLICATION, 2025-2035 (USD Billion)
    9. | | 7.3.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
    10. | | 7.3.3 BY END USE, 2025-2035 (USD Billion)
    11. | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
    12. | | 7.4.1 BY APPLICATION, 2025-2035 (USD Billion)
    13. | | 7.4.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
    14. | | 7.4.3 BY END USE, 2025-2035 (USD Billion)
    15. | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
    16. | | 7.5.1 BY APPLICATION, 2025-2035 (USD Billion)
    17. | | 7.5.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
    18. | | 7.5.3 BY END USE, 2025-2035 (USD Billion)
    19. | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
    20. | | 7.6.1 BY APPLICATION, 2025-2035 (USD Billion)
    21. | | 7.6.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
    22. | | 7.6.3 BY END USE, 2025-2035 (USD Billion)
    23. | 7.7 UK MARKET SIZE ESTIMATES; FORECAST
    24. | | 7.7.1 BY APPLICATION, 2025-2035 (USD Billion)
    25. | | 7.7.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
    26. | | 7.7.3 BY END USE, 2025-2035 (USD Billion)
    27. | 7.8 France MARKET SIZE ESTIMATES; FORECAST
    28. | | 7.8.1 BY APPLICATION, 2025-2035 (USD Billion)
    29. | | 7.8.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
    30. | | 7.8.3 BY END USE, 2025-2035 (USD Billion)
    31. | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
    32. | | 7.9.1 BY APPLICATION, 2025-2035 (USD Billion)
    33. | | 7.9.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
    34. | | 7.9.3 BY END USE, 2025-2035 (USD Billion)
    35. | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
    36. | | 7.10.1 BY APPLICATION, 2025-2035 (USD Billion)
    37. | | 7.10.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
    38. | | 7.10.3 BY END USE, 2025-2035 (USD Billion)
    39. | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
    40. | | 7.11.1 BY APPLICATION, 2025-2035 (USD Billion)
    41. | | 7.11.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
    42. | | 7.11.3 BY END USE, 2025-2035 (USD Billion)
    43. | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
    44. | | 7.12.1 BY APPLICATION, 2025-2035 (USD Billion)
    45. | | 7.12.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
    46. | | 7.12.3 BY END USE, 2025-2035 (USD Billion)
    47. | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
    48. | | 7.13.1 BY APPLICATION, 2025-2035 (USD Billion)
    49. | | 7.13.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
    50. | | 7.13.3 BY END USE, 2025-2035 (USD Billion)
    51. | 7.14 China MARKET SIZE ESTIMATES; FORECAST
    52. | | 7.14.1 BY APPLICATION, 2025-2035 (USD Billion)
    53. | | 7.14.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
    54. | | 7.14.3 BY END USE, 2025-2035 (USD Billion)
    55. | 7.15 India MARKET SIZE ESTIMATES; FORECAST
    56. | | 7.15.1 BY APPLICATION, 2025-2035 (USD Billion)
    57. | | 7.15.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
    58. | | 7.15.3 BY END USE, 2025-2035 (USD Billion)
    59. | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
    60. | | 7.16.1 BY APPLICATION, 2025-2035 (USD Billion)
    61. | | 7.16.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
    62. | | 7.16.3 BY END USE, 2025-2035 (USD Billion)
    63. | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
    64. | | 7.17.1 BY APPLICATION, 2025-2035 (USD Billion)
    65. | | 7.17.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
    66. | | 7.17.3 BY END USE, 2025-2035 (USD Billion)
    67. | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
    68. | | 7.18.1 BY APPLICATION, 2025-2035 (USD Billion)
    69. | | 7.18.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
    70. | | 7.18.3 BY END USE, 2025-2035 (USD Billion)
    71. | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
    72. | | 7.19.1 BY APPLICATION, 2025-2035 (USD Billion)
    73. | | 7.19.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
    74. | | 7.19.3 BY END USE, 2025-2035 (USD Billion)
    75. | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
    76. | | 7.20.1 BY APPLICATION, 2025-2035 (USD Billion)
    77. | | 7.20.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
    78. | | 7.20.3 BY END USE, 2025-2035 (USD Billion)
    79. | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
    80. | | 7.21.1 BY APPLICATION, 2025-2035 (USD Billion)
    81. | | 7.21.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
    82. | | 7.21.3 BY END USE, 2025-2035 (USD Billion)
    83. | 7.22 South America MARKET SIZE ESTIMATES; FORECAST
    84. | | 7.22.1 BY APPLICATION, 2025-2035 (USD Billion)
    85. | | 7.22.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
    86. | | 7.22.3 BY END USE, 2025-2035 (USD Billion)
    87. | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
    88. | | 7.23.1 BY APPLICATION, 2025-2035 (USD Billion)
    89. | | 7.23.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
    90. | | 7.23.3 BY END USE, 2025-2035 (USD Billion)
    91. | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
    92. | | 7.24.1 BY APPLICATION, 2025-2035 (USD Billion)
    93. | | 7.24.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
    94. | | 7.24.3 BY END USE, 2025-2035 (USD Billion)
    95. | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
    96. | | 7.25.1 BY APPLICATION, 2025-2035 (USD Billion)
    97. | | 7.25.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
    98. | | 7.25.3 BY END USE, 2025-2035 (USD Billion)
    99. | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
    100. | | 7.26.1 BY APPLICATION, 2025-2035 (USD Billion)
    101. | | 7.26.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
    102. | | 7.26.3 BY END USE, 2025-2035 (USD Billion)
    103. | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
    104. | | 7.27.1 BY APPLICATION, 2025-2035 (USD Billion)
    105. | | 7.27.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
    106. | | 7.27.3 BY END USE, 2025-2035 (USD Billion)
    107. | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
    108. | | 7.28.1 BY APPLICATION, 2025-2035 (USD Billion)
    109. | | 7.28.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
    110. | | 7.28.3 BY END USE, 2025-2035 (USD Billion)
    111. | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
    112. | | 7.29.1 BY APPLICATION, 2025-2035 (USD Billion)
    113. | | 7.29.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
    114. | | 7.29.3 BY END USE, 2025-2035 (USD Billion)
    115. | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
    116. | | 7.30.1 BY APPLICATION, 2025-2035 (USD Billion)
    117. | | 7.30.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
    118. | | 7.30.3 BY END USE, 2025-2035 (USD Billion)
    119. | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    120. | | 7.31.1
    121. | 7.32 ACQUISITION/PARTNERSHIP
    122. | | 7.32.1

Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2025-2035)

  • Oncology
  • Neurology
  • Cardiology
  • Infectious Diseases
  • Autoimmune Diseases

Healthcare By Technology (USD Billion, 2025-2035)

  • Molecular Imaging
  • Biomarkers
  • Genomics
  • Proteomics
  • Metabolomics

Healthcare By End Use (USD Billion, 2025-2035)

  • Hospitals
  • Diagnostic Laboratories
  • Research Institutions
  • Pharmaceutical Companies
  • Academic Institutions
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓